Centauri Therapeutics Limited

Centauri Therapeutics Limited company information, Employees & Contact Information

Centauri Therapeutics Limited is a UK-based biotechnology company focused on the discovery and development of novel molecules targeting life threatening diseases. The Alphamer technology is based on "programmable immunity" in which chemically synthesised molecules redirect naturally occurring antibodies to selected pathogens to fight the infection. The molecules have two distinct parts: one end binds a cell-surface target on the pathogen using an aptamer whereas the other end presents specific epitopes that attach to the circulating antibodies. It has been demonstrated that Alphamers have the potential to redirect pre-existing antibodies to bacteria in a specific manner and trigger an immediate antibacterial immune response, so clearing the infection. Centauri Therapeutics’ assets include specific leads and platform chemistry that is protected by strong IP and a family of granted patents and applications.

Company Details

Employees
23
Address
London, Gb
Phone
+44 (0) 1304 728610
Email
in****@****ics.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
London
Looking for a particular Centauri Therapeutics Limited employee's phone or email?

Centauri Therapeutics Limited Questions

News

Centauri Therapeutics receives an additional $5.1 M from CARB-X to progress ABX-01 lead compound to first in human clinical trials - News-Medical

Centauri Therapeutics receives an additional $5.1 M from CARB-X to progress ABX-01 lead compound to first in human clinical trials News-Medical

Centauri Therapeutics Receives an Additional $5.1M from CARB-X to Progress ABX-01 Lead Compound to First in Human Clinical Trials - Business Wire

Centauri Therapeutics Receives an Additional $5.1M from CARB-X to Progress ABX-01 Lead Compound to First in Human Clinical Trials Business Wire

Biotech Centauri Therapeutics receives £3.8m follow-on funding - UKTN

Biotech Centauri Therapeutics receives £3.8m follow-on funding UKTN

Centauri therapeutics selects first ABX-01 clinical candidate - PharmaTimes

Centauri therapeutics selects first ABX-01 clinical candidate PharmaTimes

Centauri Therapeutics Names Debra Barker as Chief Medical Officer - Contract Pharma

Centauri Therapeutics Names Debra Barker as Chief Medical Officer Contract Pharma

Centauri Therapeutics appoints Dr. Debra Barker as Chief Medical Officer - Pf Media

Centauri Therapeutics appoints Dr. Debra Barker as Chief Medical Officer Pf Media

Centauri Therapeutics Strengthens Senior Leadership Team With Three Key Appointments - Technology Networks

Centauri Therapeutics Strengthens Senior Leadership Team With Three Key Appointments Technology Networks

Centauri Therapeutics publishes proof-of-concept data demonstrating activity of a novel bifunctional immunotherapy against Gram-negative bacterial infections - Cambridge Network

Centauri Therapeutics publishes proof-of-concept data demonstrating activity of a novel bifunctional immunotherapy against Gram-negative bacterial infections Cambridge Network

Centauri Therapeutics Acquires Alphamer Technology from Altermune - Genetic Engineering and Biotechnology News

Centauri Therapeutics Acquires Alphamer Technology from Altermune Genetic Engineering and Biotechnology News

Top Centauri Therapeutics Limited Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant